Skip to main content

Octreotide Injection Shortage

Last Updated: May 14, 2024
Status: Current

Products Affected - Description
    • Octreotide Acetate injection, Avet Pharmaceuticals, 50 mcg/mL, 1 mL vial, 10 count, NDC 23155-0687-41
    • Octreotide Acetate injection, Hikma, 50 mcg/mL, 1 mL vial, 10 count, NDC 00641-6174-10
Reason for the Shortage
    • Avet did not provide a reason for the shortage.
    • Fresenius Kabi has octreotide injection available.
    • Hikma did not provide a reason for the shortage.
    • Sagent has octreotide injection available.
    • Sun Pharma discontinued Bynfezia Pen in 2021.
    • Teva discontinued octreotide in April 2022.
    • Viatris has octreotide injection available.
    • Novartis has Sandostatin available.
Available Products
    • Sandostatin injection, Novartis, 100 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0181-01
    • Sandostatin injection, Novartis, 50 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0180-01
    • Sandostatin injection, Novartis, 500 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0182-01
    • Octreotide Acetate injection, Avet Pharmaceuticals, 100 mcg/mL, 1 mL vial, 10 count, NDC 23155-0688-41
    • Octreotide Acetate injection, Avet Pharmaceuticals, 1000 mcg/mL, 5 mL vial, 1 count, NDC 23155-0686-31
    • Octreotide Acetate injection, Avet Pharmaceuticals, 200 mcg/mL, 5 mL vial, 1 count, NDC 23155-0685-31
    • Octreotide Acetate injection, Avet Pharmaceuticals, 500 mcg/mL, 1 mL vial, 10 count, NDC 23155-0689-41
    • Octreotide Acetate injection, Fresenius Kabi, 100 mcg/mL, 1 mL vial, 10 count, NDC 63323-0376-01
    • Octreotide Acetate injection, Fresenius Kabi, 1000 mcg/mL, 5 mL vial, 1 count, NDC 63323-0379-05
    • Octreotide Acetate injection, Fresenius Kabi, 200 mcg/mL, 5 mL vial, 1 count, NDC 63323-0378-05
    • Octreotide Acetate injection, Fresenius Kabi, 50 mcg/mL, 1 mL vial, 10 count, NDC 63323-0365-01
    • Octreotide Acetate injection, Fresenius Kabi, 500 mcg/mL, 1 mL vial, 10 count, NDC 63323-0377-01
    • Octreotide Acetate injection, Hikma, 1,000 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6178-01
    • Octreotide Acetate injection, Hikma, 100 mcg/mL, 1 mL vial, 10 count, NDC 00641-6175-10
    • Octreotide Acetate injection, Hikma, 200 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6177-01
    • Octreotide Acetate injection, Hikma, 500 mcg/mL, 1 mL vial, 10 count, NDC 00641-6176-10
    • Octreotide Acetate injection, Mylan Institutional (Viatris), 100 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0245-01
    • Octreotide Acetate injection, Mylan Institutional (Viatris), 50 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0239-01
    • Octreotide Acetate injection, Mylan Institutional (Viatris), 500 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0246-01
    • Octreotide Acetate injection, Sagent, 100 mcg/mL, 1 mL vial, 10 count, NDC 25021-0464-01
    • Octreotide Acetate injection, Sagent, 1000 mcg/mL, 5 mL vial, 1 count, NDC 25021-0467-05
    • Octreotide Acetate injection, Sagent, 200 mcg/mL, 5 mL vial, 1 count, NDC 25021-0466-05
    • Octreotide Acetate injection, Sagent, 50 mcg/mL, 1 mL vial, 10 count, NDC 25021-0463-01
    • Octreotide Acetate injection, Sagent, 500 mcg/mL, 1 mL vial, 10 count, NDC 25021-0465-01

Estimated Resupply Dates

    • Avet has octreotide 50 mcg/mL 1 mL vials on back order and the company estimates a release date of September 2024.
    • Hikma has octreotide 50 mcg/mL 1 mL vials on back order and the company cannot estimate a release date.

Updated

Updated May 14, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 16, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer